OC treatment increases caspase-3/7 activity, cleaving downstream targets such as PARP, a DNA repair enzyme, to execute programmed cell death, as observed in hepatocellular carcinoma (HCC) and CRC cells. The gene discussed is PARP1; the disease is colorectal carcinoma.